SEARCH

SEARCH BY CITATION

References

  • 1
    Ceci A, Felisi M, Baiardi F et al. (2006) Medicines for children licensed by the European Medicines Agency (EMEA): the balance after 10 years. European Journal of Clinical Pharmacology, 62, 947952.
  • 2
    Turner S, Longworth A, Nunn AJ, Choonara I (1998) Unlicensed and off-label drug use in paediatric wards: prospective study. BMJ, 316, 343345.
  • 3
    Conroy S, McIntyre J, Choonara I (1999) Unlicensed and off-label drug use in neonates. Archives of Disease in Childhood. Fetal and Neonatal Edition, 80, F142F145.
  • 4
    Conroy S, Choonara I, Impicciatore P et al. (2000) Survey of unlicensed and off-label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. BMJ, 320, 7982.
  • 5
    ‘t Jong GW, Vulto AG, De Hoog M, Schimmel KJ, Tibboel D, Van Den Anker JN (2000) Unapproved and off-label use of drugs in a children’s hospital. The New England Journal of Drug, 343, 1125.
  • 6
    Conroy S, Peden V (2001) Unlicensed and off-label analgesic use in paediatric pain management. Paediatric Anaesthesia, 11, 431436.
  • 7
    McDonnell F (2001) Prescription survey of unlicensed and off label medicines in pediatrics at Our Lady’s Hospital for Sick Children. Irish Pharmacy Journal (Ireland), 79, 292, 294–296.
  • 8
    Pandolfini C, Bonati M (2005) A literature review on off-label drug use in children. European Journal of Pediatrics, 164, 552558.
  • 9
    Cuzzolin L, Atzei A, Fanos V (2006) Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety. Expert Opinion on Drug Safety, 5, 703718 (review).
  • 10
    Turner S, Nunn AJ, Fielding K, Choonara I (1999) Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatrica, 88, 965968.
  • 11
    Horen B, Montastruc JL, Lapeyre-Mestre M (2002) Adverse drug reactions and off-label drug use in paediatric outpatients. British Journal of Clinical Pharmacology, 54, 665670.
  • 12
    Ufer M, Kimland E, Bergman U (2004) Adverse drug reactions and off-label prescribing for paediatric outpatients: a one-year survey of spontaneous reports in Sweden. Pharmacoepidemiology and Drug Safety, 13, 147152.
  • 13
    Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004. Official Journal of the European Union, 49. Available at: http://eur-lex.europa.eu/ (accessed 27 November 2008).
  • 14
    Barr J, Brenner-Zada G, Heiman E, Pareth G, Bulkowstein M, Greenberg R, Berkovitch M (2002) Unlicensed and off-label medication use in a neonatal intensive care unit: a prospective study. American Journal of Perinatology, 19, 6772.
  • 15
    O’Donnell CP, Stone RJ, Morley CJ (2002) Unlicensed and off-label drug use in an Australian neonatal intensive care unit. Pediatrics, 110, e52.
  • 16
    Dell’Aera M, Gasbarro AR, Padovano M et al. (2007) Unlicensed and off-label use of medicines at a neonatology clinic in Italy. Pharmacy World and Science, 29, 361367.
  • 17
    Neubert A, Dormann H, Weiss J et al. (2004) The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients. Drug Safety, 27, 10591067.
  • 18
    Turner S, Nunn AJ, Choonara I (1997) Unlicensed drug use in children in the UK. Paediatric and Perinatal Drug Therapy, 1, 5255.
  • 19
    Pandolfini C, Impicciatore P, Provasi D, Rocchi F, Campi R, Bonati M Italian Paediatric Off-label Collaborative Group (2002) Off-label use of drugs in Italy: a prospective, observational and multicentre study. Acta Paediatrica, 91, 339347.
  • 20
    ‘t Jong GW, Van Der Linden PD, Bakker EM, Van Der Lely N, Eland IA, Stricker BH, Van Den Anker JN (2002) Unlicensed and off-label drug use in a paediatric ward of a general hospital in the Netherlands. European Journal of Clinical Pharmacology, 58, 293297.
  • 21
    Di Paolo ER, Stoetter H, Cotting J et al. (2006) Unlicensed and off-label drug use in a Swiss paediatric university hospital. Swiss Medical Weekly, 136, 218222.
  • 22
    ‘t Jong GW, Vulto AG, De Hoog M, Schimmel KJ, Tibboel D, Van Den Anker JN (2001) A survey of the use of off-label and unlicensed drugs in a Dutch children’s hospital. Pediatrics, 108, 10891093.
  • 23
    Conroy S, Newman C, Gudka S (2003) Unlicensed and off label drug use in acute lymphoblastic leukaemia and other malignancies in children. Annals of Oncology, 14, 4247.
  • 24
    Bajcetic M, Jelisavcic M, Mitrovic J, Divac N, Simeunovic S, Samardzic R, Gorodischer R (2005) Off label and unlicensed drugs use in paediatric cardiology. European Journal of Clinical Pharmacology, 61, 775779.
  • 25
    Statistics Finland. (2006) Library of statistics. Available at: http://www.stat.fi/tup/tilastokirjasto/index_en.html (accessed 27 November 2008).
  • 26
    World Health Organization. (2006) The anatomical therapeutic classification system with defined daily doses (ATC/DDD). Available at: http://www.who.int/classifications/atcddd/en/ (accessed 27 November 2008).
  • 27
    Pharmaca Fennica (2001 and 2007) Lääketietokeskus Oy. Rauma, Finland: Kirjapaino Oy West Point.
  • 28
    Gavrilov V, Berkovitch M, Ling G, Brenner-Zadda G, Ligshitz M, Gorodischer R (2003) Unapproved prescriptions in two pediatric intensive care units in Israel. Current Therapeutic Research, Clinical and Experimental, 64, 734742.
  • 29
    El-Tahtawy A, Kokki H, Reidenberg BE (2006) Population pharmacokinetics of oxycodone in children 6 months to 7 years old. Journal of Clinical Pharmacology, 46, 433442.
  • 30
    National Agency for Medicines and Social Insurance Institution (2006) Finnish statistics on medicines 2005. Helsinki, Finland: Edita Prima Oy.
  • 31
    Kogan A, Katz J, Efrat R, Eidelman LA (2002) Premedication with midazolam in young children: a comparison of four routes of administration. Paediatric Anaesthesia, 12, 685689.
  • 32
    Kokki H, Räsänen I, Reinikainen M, Suhonen P, Ojanperä I (2004) Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. Clinical Pharmacokinetics, 43, 613622.
  • 33
    Kokki H, Räsänen I, Lasalmi M, Lehtola S, Ranta VP, Vanamo K, Ojanperä I (2006) Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children. Clinical Pharmacokinetics, 45, 745754.
  • 34
    Avenel S, Bomkratz A, Dassieu G, Janaud JC, Danan C (2000) The incidence of prescriptions without marketing product license in a neonatal intensive care unit. Archives de Pediatrie, 7, 143147 (French).
  • 35
    Carvalho PR, Carvalho CG, Alievi PT, Martinbiancho J, Trotta EA (2003) Prescription of drugs not appropriate for children in a Pediatric Intensive Care Unit. Jornal de Pediatria (Rio J), 79, 397402.
  • 36
    Conroy S, McIntyre J (2005) The use of unlicensed and off-label medicines in the neonate. Seminars in Fetal and Neonatal Medicine, 10, 115122 (review).
  • 37
    Directive 2001/20/EC of The European Parliament and of The Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Available at: http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/homev1.htm (accessed 27 November 2008).
  • 38
    European Agency for the Evaluation of Medicinal Products (EMEA). (1997) Human Medicines Evaluation Unit. Committee for Proprietary Medicinal Products, Committee for Proprietary Medicinal Products (CPMP), “Note for guidance on clinical investigation of medicinal products in children (CPMP/EWP/462/95)”. London: EMEA. Available at: http://www.emea.europa.eu/pdfs/human/ich/271199en.pdf (accessed 27 November 2008).
  • 39
    European Medicines Agency (EMEA). (2006) Medicines for children – the European paediatric initiative. Available at: http://www.emea.europa.eu (accessed 27 November 2008).
  • 40
    U.S. Food and Drug Administration. (2007) Pediatric exclusivity. Guidance for industry qualifying for pediatric exclusivity under section 505A of the federal food, drug, and cosmetic act. Available at: http://www.fda.gov/oc/opt/default.htm (accessed 27 November 2008).
  • 41
    European Medicines Agency (EMEA). (2007) Medicines for children. Priority list of off-patent medicines. Available at: http://www.emea.europa.eu/htms/human/paediatrics/introduction.htm (accessed 27 November 2008).
  • 42
    McKinzie JP, Wright SW, Wrenn KD (1997) Pediatric drug therapy in the emergency department: does it meet FDA-approved prescribing guidelines? American Journal of Emergency Medicine, 15, 118121.
  • 43
    Turner S (1999) Unregistered and off-label drug use in pediatric inpatients. Australian Journal of Hospital Pharmacy, 29, 265268.
  • 44
    Gavrilov V, Lifshitz M, Levy J, Gorodischer R (2000) Unlicensed and off-label medication use in a general pediatrics ambulatory hospital unit in Israel. The Israel Medical Association Journal, 2, 595597.
  • 45
    Dick A, Keady S, Mohamed F et al. (2003) Use of unlicensed and off-label medications in paediatric gastroenterology with a review of the commonly used formularies in the UK. Alimentary Pharmacology and Therapeutics, 17, 571575.
  • 46
    Serreau R, Le Heuzey MF, Gilbert A, Mouren MC, Jacqz-Aigrain E (2004) Unlicensed and off-label use of psychotropic medications in French children: a prospective study. Paediatric Perinatal Drug Therapy, 6, 1419.
  • 47
    Eiland LS, Knight P (2006) Evaluating the off-label use of medications in children. American Journal of Health-System Pharmacy, 63, 10621065.
  • 48
    Shah SS, Hall M, Goodman DM et al. (2007) Off-label drug use in hospitalized children. Archives of Pediatrics and Adolescent Medicine, 161, 282290.